Fabry disease (FD) is a lysosomal storage disorder caused by pathogenic mutations in the alpha-galactosidase A (AGALA) encoding gene region. This rare disease affects several organs including the cochlea-vestibular system. Tinnitus and sensorineural hearing loss (SNHL) are reported among otoneurological symptoms. Early and correct diagnosis of FD is important with a view to available therapy. The aim of the study was to screen for alpha-galactosidase deficiency in men with tinnitus/SNHL. A prospective multicentric study including consecutive patients with SNHL confirmed by tone audiometry or tinnitus evaluated (10/2016-8/2019). The diagnosis of AGALA deficiency was done by dry blood spot method using a threshold of 1.2 µmol/l/h. Only men aged 18-60 were included. 181 patients were subject to evaluation. SNHL was reported in 126 (70%) patients, 50 (28%) patients had unilateral, 76 (42%) patients had bilateral SNHL. Tinnitus was found in 161 (89%) patients, unilateral in 96 (53%) and bilateral in 65 (36%) patients. Suspected FD was not detected in any patient; alpha-galactosidase The AGALA values ranged 1.5-8.8 µmol/l/h, an average of 3.4 µmol/l/h. None of the 181 patients participating in the study had AGALA levels below the threshold 1.2 µmol/l/h. The occurrence of tinnitus and sensorineural hearing loss in men appears to be an irrelevant clinical sign for FD systematic screening.

Charles University 1st Faculty of Medicine General University Hospital 2nd Department of Medicine Department of Cardiovascular Medicine Prague Czech Republic

Charles University 1st Faculty of Medicine University Hospital Motol Department of Otorhinolaryngology and Head and Neck Surgery Prague Czech Republic

Charles University 3rd Faculty of Medicine Faculty Hospital Kralovske Vinohrady Department of Otorhinolaryngology Prague Czech Republic

Charles University 3rd Faculty of Medicine Military University Hospital Department of Otorhinolaryngology and Maxillofacial Surgery Prague Czech Republic

Masaryk University Medical Faculty St Anne's University Hospital Department of Otorhinolaryngology and Head and Neck Surgery Brno Czech Republic

Medical University of Vienna Clinical Institute for Pathology Vienna Austria

See more in PubMed

Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, et al. (2003). Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138(4): 338-346. DOI: 10.7326/0003-4819-138-4-200302180-00014. PubMed DOI

Friedman GS, Wik D, Silva L, Abdou JC, Meier-Kriesche HU, Kaplan B, et al. (2000). Allograft loss in renal transplant recipients with Fabry's disease and activated protein C resistance. Transplantation 69(10): 2099-2102. DOI: 10.1097/00007890-200005270-00022. PubMed DOI

Germain DP (2001). A new phenotype of Fabry disease with intermediate severity between the classical form and the cardiac variant. Contrib Nephrol 136: 234-240. DOI: 10.1159/000060194. PubMed DOI

Golan L, Goker-Alpan O, Holida M, Kantola I, Klopotowski M, Kuusisto J, et al. (2015). Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease. Drug Des Devel Ther 9: 3435-3444. DOI: 10.2147/DDDT.S80928. PubMed DOI

Hajioff D, Enever Y, Quiney R, Zuckerman J, Mackermot K, Mehta A (2003a). Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy. J Inherit Metab Dis 26(8): 787-794. DOI: 10.1023/B:BOLI.0000009948.86528.72. PubMed DOI

Hajioff D, Goodwin S, Quiney R, Zuckerman J, Macdermot KD, Mehta A (2003b). Hearing improvement in patients with Fabry disease treated with agalsidase alfa. Acta Paediatr Suppl 92(443): 28-30; discussion 27. DOI: 10.1111/j.1651-2227.2003.tb00217.x. PubMed DOI

Hegemann S, Hajioff D, Conti G, Beck M, Sunder-Plassmann G, Widmer U, et al. (2006). Hearing loss in Fabry disease: data from the Fabry Outcome Survey. Eur J Clin Invest 36(9): 654-662. DOI: 10.1111/j.1365-2362.2006.01702.x. PubMed DOI

Holy R, Prazenica P, Stolarikova E, Dosel P, Fundova P, Kovar D, Astl J (2016). Hyperbaric oxygen therapy in tinnitus with normal hearing in association with combined treatment. Undersea Hyperb Med 43(3): 201-205.

Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, Mehta AB (2008). Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 94(2): 153-158. DOI: 10.1136/hrt.2006.104026. PubMed DOI

Hughes GB, Freedman MA, Haberkamp TJ, Guay ME (1996). Sudden sensorineural hearing loss. Otolaryngol Clin North Am 29(3): 393-405. PubMed DOI

Hwu WL, Chien YH, Lee NC, Chiang SC, Dobrovolny R, Huang AC, et al. (2009). Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum Mutat 30(10): 1397-1405. DOI: 10.1002/humu.21074. PubMed DOI

Keilmann A, Hegemann S, Conti G, Hajioff D (2006). Fabry disease and the ear. In: Mehta A, Beck M, Sunder-Plassmann G (Eds) Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis.

Köping M, Shehata-Dieler W, Schneider D, Cebulla M, Oder D, Muntze J, et al. (2018). Characterization of vertigo and hearing loss in patients with Fabry disease. Orphanet J Rare Dis 13(1): 137. DOI: 10.1186/s13023-018-0882-7. PubMed DOI

Lin HY, Chong KW, Hsu JH, Yu HC, Shih CC, Huang CH, et al. (2009). High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet 2(5): 450-456. DOI: 10.1161/CIRCGENETICS.109.862920. PubMed DOI

MacDermot KD, Holmes A, Miners AH (2001). Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38(11): 750-760. DOI: 10.1136/jmg.38.11.750. PubMed DOI

Mattox DE, Lyles CA (1989). Idiopathic sudden sensorineural hearing loss. Am J Otol 10(3): 242-247.

Michaud M, Mauhin W, Belmatoug N, Bedreddine N, Garnotel R, Catros F, et al. (2020). Fabry disease: A review. Rev Med Interne S0248-8663(20)30368-4. DOI: 10.1016/j.revmed.2020.08.019. PubMed DOI

Rekova P, Sedlakova K, Dostalova G, Linhart A (2018). Fabry disease, an overview and the most common neurological manifestations. Cesk Slov Neurol N 81(2): 156-163. DOI: 10.14735/amcsnn2018156. DOI

Sergi B, Conti G, Paludetti G, Interdisciplinary Study Group on Fabry Disease (2010). Inner ear involvement in Anderson-Fabry disease: long-term follow-up during enzyme replacement therapy. Acta Otorhinolaryngol Ital 30(2): 87-93. PubMed

Schachern PA, Shea DA, Paparella MM, Yoon TH (1989). Otologic histopathology of Fabry's disease. Ann Otol Rhinol Laryngol 98(5 Pt 1): 359-363. DOI: 10.1177/000348948909800509. PubMed DOI

Schuknecht HF, Gacek MR (1993). Cochlear pathology in presbycusis. Ann Otol Rhinol Laryngol 102(1 Pt 2): 1-16. DOI: 10.1177/00034894931020S101. PubMed DOI

Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, et al. (2006). High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 79(1): 31-40. DOI: 10.1086/504601. PubMed DOI